Advance of molecular imaging probes targeted for EphB4 receptor

doi:10.3760/cma.j.issn.1673-422X.2016.11.010

Abstract

Abstract: The erythropoietinproducing hepatocellular receptor (Eph) B4 receptor is closely associated with tumor growth and angiogenesis, which is overexpressed in a wide variety of tumors. Molecular probes targeted for EphB4 receptor can improve the accuracy and specificity of tumor diagnosis. A lot of molecular probes targeted for EphB4 receptor have been designed, which are expected to provide new means for the early diagnosis and therapeutics of tumors.

Key words: Receptor, EphB4, Neoplasms, Nuclear medicine, Molecular probes

Xie Qinghua, Zhu Hua, Liu Fei, Han Xuedi, Xia Chuanqin, Yang Zhi. Advance of molecular imaging probes targeted for EphB4 receptor[J]. Journal of International Oncology, 2016, 43(11): 841-844.

References

［1］ Mosch B, Reissenweber B, Neuber C, et al. Eph receptors and ephrin ligands: important players in angiogenesis and tumor angiogenesis［J］. J Oncol, 2010, 2010: 135285. DOI: 10.1155/2010/135285. ［2］ Huang G, Li M. The role of EphB4 and IGFIR expression in breast cancer cells［J］. Int J Clin Exp Pathol, 2015, 8(5): 59976004. ［3］ Ferguson BD, Liu R, Rolle CE, et al. The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target［J］. PLoS One, 2013, 8(7): e67668. DOI: 10.1371/journal.pone.0067668. ［4］ Hasina R, Mollberg N, Kawada I, et al. Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers［J］. Cancer Res, 2013, 73(1): 184-194. DOI: 10.1158/00085472.CAN120915. ［5］ Chen T, Liu X, Yi S, et al. EphB4 is overexpressed in gliomas and promotes the growth of glioma cells［J］. Tumor Biol, 2013, 34(1): 379-385. DOI: 10.1007/s13277-012-0560-7. ［6］ Tu Y, He S, Fu J, et al. Expression of EphrinB2 and EphB4 in glioma tissues correlated to the progression of glioma and the prognosis of glioblastoma patients［J］. Clin Transl Oncol, 2012, 14(3): 214220. DOI: 10.1007/s1209401207862. ［7］ Li M, Zhao ZW, Zhang Y, et al. Overexpression of Ephb4 is associated with carcinogenesis of gastric cancer［J］. Dig Dis Sci, 2011, 56(3): 698-706. DOI: 10.1007/s10620-010-1346-7. ［8］ Li M, Zhao Z. Clinical implications of EphB4 receptor expression in pancreatic cancer［J］. Mol Biol Rep, 2013, 40(2): 1735-1741. DOI: 10.1007/s1103301222245. ［9］ Liu R, Ferguson BD, Zhou Y, et al. EphB4 as a therapeutic target in mesothelioma［J］. BMC Cancer, 2013, 13: 269. DOI: 10.1186/1471-2407-13-269. ［10］ Lisle JE, MertensWalker I, Rutkowski R, et al. Eph receptors and their ligands: promising molecular biomarkers and therapeutic targets in prostate cancer［J］. Biochim Biophys Acta, 2013, 1835(2): 243-257. DOI: 10.1016/j.bbcan.2013.01.003. ［11］ Xi H Q, Wu XS, Wei B, et al. Eph receptors and ephrins as targets for cancer therapy［J］. J Cell Mol Med, 2012, 16(12): 2894-2909. DOI: 10.1111/j.15824934.2012.01612.x. ［12］ Barquilla A, Pasquale EB. Eph receptors and ephrins: therapeutic opportunities［J］. Annu Rev Pharmacol Toxicol, 2015, 55: 465-487. DOI: 10.1146/annurevpharmtox-011112-140226. ［13］ GuijarroMuoz I, Sánchez A, MartínezMartínez E, et al. Gene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab［J］. Med Oncol, 2013, 30(2): 572. DOI: 10.1007/s12032-013-0572-1. ［14］ Xiong C, Huang M, Zhang R, et al. In vivo smallanimal PET/CT of EphB4 receptors using 64Culabeled peptide［J］. J Nucl Med, 2011, 52(2): 241-248. DOI: 10.2967/jnumed.110.081943. ［15］ Huang M, Xiong C, Lu W, et al. Dualmodality micropositron emission tomography/computed tomography and nearinfrared fluorescence imaging of EphB4 in orthotopic glioblastoma xenograft models［J］. Mol Imaging Biol, 2014, 16(1): 74-84. DOI: 10.1007/s11307-013-0674-3. ［16］ Zhang R, Xiong C, Huang M, et al. Peptideconjugated polymeric micellar nanoparticles for Dual SPECT and optical imaging of EphB4 receptors in prostate cancer xenografts［J］. Biomaterials, 2011, 32(25): 5872-5879. DOI: 10.1016/j.biomaterials.2011.04.070. ［17］ Noberini R, Mitra S, Salvucci O, et al. PEGylation potentiates the effectiveness of an antagonistic peptide that targets the EphB4 receptor with nanomolar affinity［J］. PLoS One, 2011, 6(12): e28611. DOI: 10.1371/journal.pone.0028611. ［18］ Chen FY, Yan JJ, Yi HX, et al. TNYL peptide functional chitosangstearate conjugate micelles for tumor specific targeting［J］. Int J Nanomedicine, 2014, 9: 4597-4608. DOI: 10.2147/IJN.S69572. ［19］ Wang Z, Sun J, Qiu Y, et al. Specific photothermal therapy to the tumors with high EphB4 receptor expression［J］. Biomaterials, 2015, 68: 32-41. DOI: 10.1016/j.biomaterials.2015.07.058. ［20］ You J, Zhang R, Xiong C, et al. Effective photothermal chemotherapy using doxorubicinloaded gold nanospheres that target EphB4 receptors in tumors［J］. Cancer Res, 2012, 72(18): 4777-4786. DOI: 10.1158/00085472.CAN-12-1003. ［21］ Xiong CY, Cao QZ, Li C. PET/CT imaging of EphB4 receptors in melanoma xenograft with a 68Galabeled cyclic TNYLRAW peptide［J］. J Nucl Med, 2013, 54 (Suppl-2): 1042. ［22］ Kaur S, Venktaraman G, Jain M, et al. Recent trends in antibodybased oncologic imaging［J］. Cancer Lett, 2012, 315(2): 97-111. DOI: 10.1016/j.canlet.2011.10.017. ［23］ Krasnoperov V, Kumar SR, Ley E, et al. Novel EphB4 monoclonal antibodies modulate angiogenesis and inhibit tumor growth［J］. Am J Pathol, 2010, 176(4): 2029-2038. DOI: 10.2353/ajpath.2010.090755. ［24］ Liu S, Li D, Park R, et al. PET imaging of colorectal and breast cancer by targeting EphB4 receptor with 64Culabeled hAb47 and hAb131 antibodies［J］. J Nucl Med, 2013, 54(7): 1094-1100. DOI: 10.2967/jnumed.112.116822. ［25］ Li D, Liu S, Liu R, et al. Targeting the EphB4 receptor for cancer diagnosis and therapy monitoring［J］. Mol Pharm, 2013, 10(1): 329-336. DOI: 10.1021/mp300461b. ［26］ Li D, Liu S, Liu R, et al. EphB4targeted imaging with antibody h131, h131F(ab′)2 and h131Fab［J］. Mol Pharm, 2013, 10(12): 4527-4533. DOI: 10.1021/mp400354y. ［27］ Mamat C, Mosch B, Neuber C, et al. Fluorine18 radiolabeling and radiopharmacological characterization of a benzodioxolylpyrimidinebased radiotracer targeting the receptor tyrosine kinase EphB4［J］. Chem Med Chem, 2012, 7(11): 1991-2003. DOI: 10.1002/cmdc.201200264. ［28］ Ebert K, Wiemer J, Caballero J, et al. Development of indazolylpyrimidine derivatives as highaffine EphB4 receptor ligands and potential PET radiotracers［J］. Bioorg Med Chem, 2015, 23(17): 6025-6035. DOI: 10.1016/j.bmc.2015.06.040.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.